The short answer
Two frequently cited studies in the Journal of Orthopaedic Research examined BPC-157 in musculoskeletal models: Krivic and colleagues on Achilles tendon detachment in 2006, and Cerovecki and colleagues on ligament healing in 2010. Both used rat models.
Key facts
- Achilles model
- Krivic, J Orthop Res 2006 (PMID 16583442)
- Ligament model
- Cerovecki, J Orthop Res 2010 (PMID 20225319)
- Model organism
- Rat
- Journal
- Journal of Orthopaedic Research
- Human equivalent
- Phase 2 in hamstring strain, recruiting
- Reported result
- Improved healing measures in the models
The two studies
Krivic and colleagues examined Achilles tendon detachment in the rat, published in the Journal of Orthopaedic Research in 2006, reporting effects on the tendon-to-bone unit. Cerovecki and colleagues reported that pentadecapeptide BPC 157 improved ligament healing in the rat, in the same journal in 2010. Both appear in a mainstream orthopaedic journal rather than a specialist peptide publication.
Why musculoskeletal models are attractive here
Tendon and ligament heal slowly and poorly, with limited vascular supply, which makes them a demanding test and a clinically meaningful target. They also permit reasonably objective endpoints. Mechanical testing of a healed tendon gives a number rather than an impression.
Research material referenced
BPC-157 5mg, third-party HPLC tested
What a rat tendon model can establish
That a compound alters a healing measure under controlled conditions in that species. Rat tendon healing differs from human in scale, loading and time course, and a surgically created injury differs from a strain sustained in use. These are the standard limitations of animal musculoskeletal models rather than criticisms of these particular studies.
The trial that tests the translation
NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial of BPC 157 in acute hamstring muscle strain. 120 participants, sponsored by Hudson Biotech, started 2 February 2026 with primary completion due 14 February 2027. It is the direct human counterpart to this preclinical thread, which makes the tendon and ligament literature unusually consequential: it is about to be tested.
What is claimed here
Nothing. These are reports of what specific studies measured in rat models, plus a registered trial that has not reported. Material supplied for laboratory research has no relationship to that trial, and no claim is made that BPC-157 heals tendon, ligament or muscle in any person.
Frequently asked questions
Has BPC-157 been studied in tendon injury?
In rat models. Krivic 2006 examined Achilles detachment and Cerovecki 2010 examined ligament healing, both in the Journal of Orthopaedic Research.
Is there human evidence?
A Phase 2 trial in acute hamstring muscle strain is recruiting, with primary completion due February 2027. No result exists yet.
Do rat tendon results transfer to people?
Not automatically. Scale, loading and healing time course all differ, and a surgical injury differs from a strain sustained in use.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedKrivic A et al., Achilles detachment in rat and BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: BPC 157 Phase 2 in hamstring strain (NCT07437547)clinicaltrials.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- Growth Factor Signalling in the BPC-157 LiteratureReported interactions with growth-factor systems are part of the multi-pathway description. What that means when no receptor for the peptide is known.
- BPC-157 Studied Effects, Sorted by EvidenceGastrointestinal, tendon, ligament and vascular models, plus clinical development as PL-14736 and a Phase 2 recruiting now. Ranked by how well established.
- BPC-157 Side Effects and the Absence of Human DataNo controlled human safety study exists. What the rodent literature reports, the theoretical concern that follows from its own mechanism, and what nobody knows.
- What BPC-157 Is Claimed to Do, and in Which SpeciesTendon, ligament, gut and vascular findings - almost entirely in rats. What has been demonstrated, in which species, and why no human timeline exists.
- Is BPC-157 Legal?Not a controlled substance, and not a licensed medicine either. What that gap means, plus the FDA compounding decision and its prohibited status in sport.